Organizational Communication

: Lipobay /cerivastatin Case StudyIntroductionLipobay , also known as cerivastatin , is a cholesterol-reducing dose prescribed to patients suffering from high cholesterol levels which is the prime risk factor for a number of cardiovascular diss . It is one of the four drugs that are responsible for 0 .5 billion Euro worth of revenues yearly in this sedulousness (Berg Welge , 2006 . On August 8 2001 , the drug was recalled by the pharmaceutical order Bayer AG after the drug has been linked with Rhabdomyolysis , a muscular complaint that bugger offs muscle fibers to breakdown and releases the chemical myoglobin into the bloodstream . This disease had findd 31 deaths in the United States , 52 elsewhere in the world and about 1000 severe cases of the disease (Berge Weldge , 2006 , Heidelberg , 2001 , Rhabdomyolysis 2007 . This case opened arenas for the examination of conflicts within the pharmaceutical industry , specifically transparency in drug development , as well as how global competition and shareholders may cause a company to overlook warnings and get the wrong idea about reports given (Berg Welge , 2006AnalysisLife Cycle Stakeholders of the IssueThe life cycle of the Lipbay /Baycol case began when reports about patients experiencing adverse side effects of the drug after it was approved by the Federal Institute for Drugs and aesculapian Devices in Germany , or BfArM , in 1997 . The reports received include knowledge that Lipobay /Baycol had harmful effects on the muscular outline of the patients taking it . Further studies of the side effects of the drug included the adverse reactions that were found on the skeletal system colorful and skin of the patient , and even death . By the depot of 2001 , more than 1000 cases of skeletal and muscular deterioration befool been linked to Lipobay /Baycol worldwide , as well as 52 deaths .

This caused Bayer AG to recall Lipobay /Baycol from the marketplace in August 2001 (Berg Welge 2006 , The BfArM and its Tasks , 2008After the recall of the drug , the Federal parson of Health requested a comprehensive report on the matter . Initially , the BfArM stated that the risk-reducing measures being adopted were unceasing and reasonable and needed no further action . It was plainly after the BfArM requested Bayer AG to make up a report with the latest information of the matter that they had realized that they were not properly updated to be able to have the necessary actions make . The Federal Ministry of Health had concluded that this decision of Bayer cause , the company to breach of Section 29 , paragraph 1 of the Medication Act , which stipulates that the responsible superior authority is to be informed by pharmaceutical companies of each case of a known suspicion of serious side effects or as serious interaction with other medication in addition to new knowledge that is not included in the approval documents (Berg Welge , 2006 ,. 247 . In line with this , Bayer AG was instructed to submit these documents to the BfArM (Berg Welge , 2006Bayer AG had refuted allegations stating that they had informed the company...If you want to get a in force(p) essay, order it on our website: Ordercustompaper.com

If you want to get a full essay, wisit our page: write my paper